Paul S Rennie Selected Research

Androgen Antagonists (Antiandrogens)

10/2017	Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.
12/2016	Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
11/2014	Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.
12/2013	Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.
11/2013	Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer.
2/2013	Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.
1/2013	Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
12/2011	Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
5/2007	DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul S Rennie Research Topics

Disease

81	Prostatic Neoplasms (Prostate Cancer) 10/2021 - 05/2002
55	Neoplasms (Cancer) 10/2021 - 06/2004
4	Breast Neoplasms (Breast Cancer) 02/2018 - 01/2010
4	Urinary Bladder Neoplasms (Bladder Cancer) 01/2017 - 06/2008
3	Adenocarcinoma 12/2018 - 07/2007
3	Carcinogenesis 01/2012 - 07/2007
2	Carcinoma (Carcinomatosis) 10/2017 - 12/2009
2	Disease Progression 03/2013 - 06/2012
2	Neoplasm Metastasis (Metastasis) 03/2012 - 07/2007
1	Brain Neoplasms (Brain Tumor) 11/2018
1	Glioblastoma (Glioblastoma Multiforme) 01/2018
1	Endocrine Gland Neoplasms (Cancer, Endocrine) 10/2017
1	Malaria 01/2017
1	Urologic Neoplasms (Urological Cancer) 06/2016
1	Glioma (Gliomas) 05/2016
1	Prostatic Intraepithelial Neoplasia 05/2016

Drug/Important Bio-Agent (IBA)

54	Androgen Receptors (Androgen Receptor)IBA 10/2021 - 05/2002
32	AndrogensIBA 10/2021 - 05/2002
20	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2003
16	Pharmaceutical PreparationsIBA 01/2020 - 05/2011
14	Hormones (Hormone)IBA 11/2018 - 06/2004
12	LigandsIBA 03/2021 - 12/2002
12	Transcription Factors (Transcription Factor)IBA 01/2020 - 06/2013
9	Androgen Antagonists (Antiandrogens)IBA 10/2017 - 05/2007
8	enzalutamideIBA 12/2016 - 02/2013
6	Small Interfering RNA (siRNA)IBA 01/2021 - 11/2006
6	DNA (Deoxyribonucleic Acid)IBA 10/2017 - 05/2003
6	Prostate-Specific Antigen (Semenogelase)IBA 01/2016 - 11/2006
4	LuciferasesIBA 01/2018 - 11/2006
4	Carboxy-LyasesIBA 06/2012 - 01/2007
4	Levodopa (L Dopa)FDA LinkGeneric 06/2012 - 01/2007
3	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 10/2017 - 12/2014
3	Phosphotransferases (Kinase)IBA 05/2016 - 03/2006
3	AntigensIBA 01/2016 - 03/2007
3	EnzymesIBA 12/2013 - 01/2007
3	Messenger RNA (mRNA)IBA 07/2012 - 03/2012
3	bicalutamide (Casodex)FDA LinkGeneric 06/2012 - 10/2003
3	beta CateninIBA 04/2005 - 05/2002
2	ProdrugsIBA 10/2021 - 01/2011
2	Oncogene Proteins (Oncogene Protein)IBA 01/2021 - 02/2019
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2010
2	Activating Transcription Factor 4IBA 01/2021 - 01/2019
2	Indicators and Reagents (Reagents)IBA 01/2019 - 01/2017
2	SteroidsIBA 11/2018 - 01/2016
2	Orphan Nuclear ReceptorsIBA 11/2018 - 12/2014
2	Furylfuramide (AF2)IBA 02/2018 - 02/2015
2	Estrogen ReceptorsIBA 02/2018 - 12/2014
2	Proteoglycans (Proteoglycan)IBA 01/2017 - 04/2005
2	Steroid Synthesis InhibitorsIBA 12/2016 - 07/2015
2	Viral DNAIBA 05/2016 - 05/2010
2	Lipid NanoparticlesIBA 01/2016 - 09/2012
2	Dihydrotestosterone (Androstanolone)IBA 03/2013 - 11/2007
2	Carbidopa (Lodosyn)FDA LinkGeneric 06/2012 - 06/2012
2	AntibodiesIBA 01/2011 - 03/2010
2	Trastuzumab (Herceptin)FDA Link 01/2011 - 03/2010
2	Firefly LuciferasesIBA 01/2011 - 06/2008
2	5' Untranslated Regions (5' UTR)IBA 05/2010 - 03/2010
2	Complementary DNA (cDNA)IBA 12/2009 - 03/2007
2	AutoantibodiesIBA 12/2009 - 03/2007
2	Tetracycline (Achromycin)FDA LinkGeneric 01/2009 - 06/2007
2	Versicans (Versican)IBA 11/2007 - 04/2005
2	MetriboloneIBA 11/2007 - 11/2006
2	probasinIBA 03/2007 - 06/2004
2	TCF Transcription FactorsIBA 04/2005 - 08/2003
1	Proto-Oncogene Proteins c-etsIBA 01/2020
1	RNA Precursors (Precursor, mRNA)IBA 02/2019
1	Heterogeneous Nuclear Ribonucleoprotein A1IBA 02/2019
1	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 02/2019
1	Protein Isoforms (Isoforms)IBA 02/2019
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 02/2019
1	MKC8866IBA 01/2019
1	Ribonucleases (Ribonuclease)IBA 01/2019
1	protopanaxadiolIBA 04/2018
1	GinsenosidesIBA 04/2018
1	Caspase 3 (Caspase-3)IBA 04/2018
1	bcl-2-Associated X Protein (bcl 2 Associated X Protein)IBA 04/2018
1	Therapeutic UsesIBA 01/2018
1	TOPSIBA 01/2018
1	ChromatinIBA 10/2017
1	4,4'-dibenzamido-2,2'-stilbenedisulfonic acidIBA 10/2017
1	Semaphorins (Semaphorin)IBA 02/2017
1	Cisplatin (Platino)FDA LinkGeneric 01/2017
1	GlycosaminoglycansIBA 01/2017
1	SugarsIBA 01/2017
1	Recombinant ProteinsIBA 01/2017
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2017
1	chondroitin sulfate proteoglycan 4IBA 01/2017
1	abirateroneIBA 12/2016
1	Eukaryotic Initiation Factor-4EIBA 05/2016
1	SurvivinIBA 05/2016
1	Choline KinaseIBA 05/2016
1	Molecular Chaperones (Chaperone, Molecular)IBA 05/2016
1	Cell-Free Nucleic AcidsIBA 01/2016
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2016

Therapy/Procedure

35	Therapeutics 10/2021 - 05/2003
34	Castration 10/2021 - 11/2006
3	Intravenous Injections 01/2016 - 03/2010
2	Oncolytic Virotherapy 01/2018 - 06/2016
1	Drug Therapy (Chemotherapy) 01/2017
1	Neoadjuvant Therapy 01/2017